The Contribution of Oral and Inhaled Glucocorticoids to Adrenal Insufficiency in Asthma

Exposure to any form of glucocorticoid preparation is associated with a risk of adrenal insufficiency (AI). To establish the contribution of oral corticosteroid (OCS) and inhaled corticosteroid (ICS) exposure to the risk of AI in a cohort of patients (n = 80) with severe, uncontrolled asthma. We com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2022-10, Vol.10 (10), p.2614-2623
Hauptverfasser: Brennan, Vincent, Martin-Grace, Julie, Greene, Garrett, Heverin, Karen, Mulvey, Christopher, McCartan, Tom, Lombard, Lorna, Walsh, Joanne, Hale, Elaine Mac, Srinivasan, Shari, O’Reilly, Michael W., Thompson, Chris J., Costello, Richard W., Sherlock, Mark
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Exposure to any form of glucocorticoid preparation is associated with a risk of adrenal insufficiency (AI). To establish the contribution of oral corticosteroid (OCS) and inhaled corticosteroid (ICS) exposure to the risk of AI in a cohort of patients (n = 80) with severe, uncontrolled asthma. We compiled individualized cumulative OCS and ICS exposure data using a combination of health care records and electronic inhaler monitoring using an Inhaler Compliance Assessment device and estimated the risk of AI for each participant using a morning serum cortisol concentration. The predicted prevalence of AI based on morning cortisol concentrations was 25% (20 of 80). Participants on maintenance OCS therapy had the highest risk of AI at 60% (6 of 10) compared with 17% (11 of 65) in those with no recent OCS exposure. Morning serum cortisol correlated negatively with both OCS exposure (mg/kg prednisolone) (r = −0.4; P 
ISSN:2213-2198
2213-2201
DOI:10.1016/j.jaip.2022.05.031